Clinical Trials Logo

Clinical Trial Summary

The purpose of this research study is to learn more about a new combination of drugs being given to treat pancreatic cancer. The drugs being tested are BMS-813160, nivolumab, gemcitabine, and nab-paclitaxel. The investigators will be looking at both the side effects and the way the disease responds to treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03496662
Study type Interventional
Source Washington University School of Medicine
Contact Kian-Huat Lim, M.D., Ph.D.
Phone (314) 362-6157
Email kian-huat.lim@wustl.edu
Status Recruiting
Phase Phase 1/Phase 2
Start date August 31, 2018
Completion date January 31, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT03257150 - A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer N/A
Not yet recruiting NCT03634332 - Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC Phase 2
Recruiting NCT03267316 - A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors Phase 1/Phase 2
Completed NCT02259114 - A Dose-Finding Study of OTX105/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) Phase 1
Recruiting NCT02926183 - Study of NAC of GA Therapy for Patients With BRPC Phase 2
Not yet recruiting NCT02570529 - Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Phase 4
Recruiting NCT02050997 - Plasma Biomarkers P-DAC, V1
Not yet recruiting NCT01942629 - Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas N/A
Not yet recruiting NCT03608631 - iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation Phase 1
Recruiting NCT01983410 - A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma
Not yet recruiting NCT02607826 - Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors N/A
Terminated NCT01962909 - Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer Phase 0
Active, not recruiting NCT02527434 - Study of Tremelimumab in Patients With Advanced Solid Tumors Phase 2
Active, not recruiting NCT01013649 - Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Phase 3
Not yet recruiting NCT03316326 - S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT02790944 - Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer
Recruiting NCT03525392 - Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. Phase 1/Phase 2
Not yet recruiting NCT02440958 - Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial Phase 2
Completed NCT01580397 - Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Phase 2
Terminated NCT00307723 - Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer Phase 1/Phase 2